Tonix Pharmaceuticals Holding EBIT

The latest EBIT for TNXP is $-160M as of June 2026. That compares with $-82M in the prior-year period — down 98.0% year over year. That is below the Healthcare sector average of $23B. Investors often review this figure alongside Tonix Pharmaceuticals Holding's historical trend and sector peers before judging valuation or financial health.

Over the past year, TNXP's EBIT moved from $-82M to $-160M — a 98.0% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Tonix Pharmaceuticals Holding's operating scale or balance-sheet position.

Against Healthcare companies, TNXP currently prints $-160M for EBIT, while the sector average sits near $23B. That is roughly 100.7% below the sector mean. Large gaps often invite a closer look at Tonix Pharmaceuticals Holding's growth, margins, and balance sheet.

A EBIT figure of $-160M for TNXP is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $23B. Explore the charts below for those layers of context.

After noting TNXP's EBIT ($-160M), review year-over-year change from $-82M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.